Alkem Laboratories Limited has announced the incorporation of a wholly owned subsidiary (WOS) in Dubai, UAE, named Alkem Pharmaceuticals Scientific Office FZ LLC. This new entity is being established to undertake the manufacturing and registration of products, excluding trading activities. The acquisition involved a cash consideration of AED 3,670,000 for 3,670 Equity Shares, representing a 100% stake. The WOS was incorporated on February 4, 2026.
Establishment of New Overseas Subsidiary
Alkem Laboratories Limited has officially completed the incorporation of a new Wholly Owned Subsidiary (WOS) in the United Arab Emirates (UAE). The newly formed entity is named Alkem Pharmaceuticals Scientific Office FZ LLC, based in Dubai. This strategic move was formalized through a filing dated March 30, 2026.
Details of the Acquisition and Stake
Alkem Laboratories has acquired a 100% stake in the new subsidiary. The total cost of acquisition amounted to AED 3,670,000. This consideration was paid for the subscription of 3,670 Equity Shares, with each share valued at AED 1,000. The WOS has an Authorized and Subscribed Share Capital both totaling AED 3,670,000.
Business Objectives
The primary purpose for incorporating this WOS is to facilitate the manufacturing of products and the process of obtaining product registrations in the region. It is explicitly noted that the entity will not undertake trading activities. The Date of Incorporation for the WOS was February 4, 2026.
Related Party Status and Approvals
Since the WOS is wholly owned by Alkem Laboratories Limited, it is classified as a related party transaction. However, the subscription was completed on an “arm’s length” basis. Furthermore, the documents mention that related approvals from the UAE’s Ministry of Health and Prevention are currently delayed, presumably due to the ongoing regional conflict. The turnover for the last three years is listed as Not Applicable.
Source: BSE
